Division of Hematology and Oncology, Department of Internal Medicine, UC Davis Cancer Center, Sacramento, CA 95817, USA.
Anticancer Res. 2010 Nov;30(11):4573-8.
To determine if the drug doses and administration schedules of carboplatin and gemcitabine combination affect antitumor effects.
The inhibition of cell viability was measured by MTT assay. Median effect analysis was conducted to determine the cytotoxicity activity of carboplatin and gemcitabine combination. Cell cycle changes were analyzed by flow cytometry.
Synergism was observed when the bladder cancer cell line 5637 cells were treated with gemcitabine followed by carboplatin or concurrent carboplatin/gemcitabine. In contrast, moderate antagonism was observed when cells were treated with carboplatin followed by gemcitabine. Cell cycle analysis showed that the combined effect of these two drugs was cell cycle disturbance.
Different doses and administration schedules affect the antitumor effect of carboplatin/gemcitabine combination that may have clinical significance in the treatment for bladder cancer.
确定卡铂和吉西他滨联合用药的剂量和给药方案是否会影响抗肿瘤效果。
通过 MTT 测定法来测量细胞活力的抑制作用。采用中值效应分析来确定卡铂和吉西他滨联合用药的细胞毒性活性。通过流式细胞术分析细胞周期变化。
当膀胱癌细胞系 5637 细胞先用吉西他滨处理，然后再用卡铂或同时用卡铂/吉西他滨处理时，观察到协同作用。相比之下，当先用卡铂处理然后再用吉西他滨处理细胞时，观察到中度拮抗作用。细胞周期分析表明，这两种药物的联合作用是细胞周期紊乱。
不同的剂量和给药方案会影响卡铂/吉西他滨联合用药的抗肿瘤效果，这在膀胱癌的治疗中可能具有临床意义。
